Home » Business News » 2011 » January » January 25, 2011

Q-Med brings forward the date for the Year-End Report 2010

January 25, 2011 - London

The Year-End Report 2010 for Q-Med AB will be published at 08.00 a.m. on Monday January 31, 2011, instead of, as earlier announced, on February 11, 2011.

Galderma Holding AB, a company wholly-owned by Galderma Pharma S.A., announced on December 13, 2010 a public takeover offer to the shareholders of Q-Med to tender all of their shares in Q-Med to Galderma. 

In the light of this the Board of Q-Med AB considers that it is important that the shareholders receive information that is as up-to-date as possible with regard to the company's results and financial position. The Board has therefore decided to bring forward the time when the company's year-end report for 2010 is published to 8 a.m. on January 31.  


Queries should be addressed to:
Anders Milton, Chairman of the Bid Committee and Director of the Board
Tel: +46 (0) 70-526 46 02   


Q-Med provides the information in this press release in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 09.00 (CET) on 25 January, 2011. 

Q-Med ABis a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta® for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.   

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: Web: 

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Q-Med AB via Thomson Reuters ONE


Comment on this story